Sheriff M H, Yayha T, Lee H A
Lancet. 1978 Jan 21;1(8056):118-20. doi: 10.1016/s0140-6736(78)90418-x.
In renal-transplant patients in whom azathioprine therapy was withdrawn early because of bone-marrow suppression no rebound graft rejection was noted. Any subsequent rejection episodes were satisfactorily treated with methylprednisolone pulse therapy. Of 15 patients in whom azathioprine was stopped electively after at least 2 years, only 1 had a subsequent cellular rejection. It is concluded that azathioprine may not have a major role in the immunosuppressive management of renal-transplant patients. If azathioprine has to be stopped there seems to be no good indication for restarting it.
在因骨髓抑制而早期停用硫唑嘌呤治疗的肾移植患者中,未观察到移植肾排斥反应的反弹。任何随后的排斥反应发作均通过甲泼尼龙冲击疗法得到了满意的治疗。在至少2年后选择性停用硫唑嘌呤的15例患者中,只有1例随后发生了细胞性排斥反应。得出的结论是,硫唑嘌呤在肾移植患者的免疫抑制管理中可能没有主要作用。如果必须停用硫唑嘌呤,似乎没有重新开始使用它的充分指征。